ZYUS Life Sciences (ZYUS) Stock Overview
Manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ZYUS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ZYUS Life Sciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.82 |
| 52 Week High | CA$1.10 |
| 52 Week Low | CA$0.55 |
| Beta | 0 |
| 1 Month Change | 13.89% |
| 3 Month Change | 2.50% |
| 1 Year Change | -21.90% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -28.70% |
Recent News & Updates
Shareholder Returns
| ZYUS | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 6.5% | -6.5% | 0.4% |
| 1Y | -21.9% | -57.6% | 15.7% |
Return vs Industry: ZYUS exceeded the Canadian Pharmaceuticals industry which returned -58.2% over the past year.
Return vs Market: ZYUS underperformed the Canadian Market which returned 17% over the past year.
Price Volatility
| ZYUS volatility | |
|---|---|
| ZYUS Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 13.4% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in CA Market | 18.6% |
| 10% least volatile stocks in CA Market | 4.0% |
Stable Share Price: ZYUS has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: ZYUS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Brent Zettl | www.zyus.com |
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.
ZYUS Life Sciences Corporation Fundamentals Summary
| ZYUS fundamental statistics | |
|---|---|
| Market cap | CA$62.68m |
| Earnings (TTM) | -CA$34.43m |
| Revenue (TTM) | CA$481.00k |
Is ZYUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYUS income statement (TTM) | |
|---|---|
| Revenue | CA$481.00k |
| Cost of Revenue | CA$1.44m |
| Gross Profit | -CA$957.00k |
| Other Expenses | CA$33.47m |
| Earnings | -CA$34.43m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | -198.96% |
| Net Profit Margin | -7,157.17% |
| Debt/Equity Ratio | -132.1% |
How did ZYUS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/05 13:03 |
| End of Day Share Price | 2025/06/02 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ZYUS Life Sciences Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Keywood | Stifel Canada |
| Andrew Partheniou | Stifel Canada |